ubenimex has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ino, K; Kajiyama, H; Kikkawa, F; Mizutani, S; Nawa, A; Shibata, K; Terauchi, M | 1 |
| Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Tsukamoto, H | 1 |
2 other study(ies) available for ubenimex and Disease Exacerbation
| Article | Year |
|---|---|
Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.
Topics: Animals; CD13 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Female; Humans; Leucine; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Ovarian Neoplasms | 2007 |
Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer.
Topics: Animals; CD13 Antigens; Disease Progression; Female; HeLa Cells; Humans; In Situ Nick-End Labeling; Leucine; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Radiation Tolerance; Radiotherapy; Uterine Cervical Neoplasms | 2008 |